Patents by Inventor Sei-Hyun Choi

Sei-Hyun Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250109135
    Abstract: Provided are an isoindolinone derivative compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, as caspase inhibitors, which exhibits an excellent interleukin-1?(IL-1?) reducing effect and an excellent apoptosis-reducing effect, thus exhibits excellent activity as a caspase inhibitor, and thus can be used for the prevention or treatment of caspase-related diseases in the medical and pharmaceutical fields.
    Type: Application
    Filed: January 3, 2023
    Publication date: April 3, 2025
    Applicant: INNOVO THERAPEUTICS INC.
    Inventors: Sei Hyun CHOI, Hak Joong KIM, Yu Rim LEE, Sun Ho JUNG, Haushabhau Shivaji PAGIRE
  • Patent number: 12257341
    Abstract: The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: March 25, 2025
    Assignee: LG CHEM, LTD.
    Inventors: Sung Won Kim, Jae Uk Baek, Hyun Seo Park, Myung Won Jin, Jung Gyu Park, Bok Tae Kim, Sei Hyun Choi
  • Publication number: 20230414601
    Abstract: The present invention relates to an injectable pharmaceutical composition containing a caspase inhibitor, and a preparation method therefor, and, more specifically, to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising: as an active ingredient, (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, which is a caspase inhibitor, or a pharmaceutically acceptable salt or isomer thereof; and, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).
    Type: Application
    Filed: November 29, 2021
    Publication date: December 28, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Seok Cheol YOO, Sung Won KIM, Jung Gyu PARK, Sei Hyun CHOI, Hee Dong PARK, Jae Uk BAEK
  • Publication number: 20230310412
    Abstract: The present invention relates to a use of a caspase inhibitor for alleviating or treating osteoarthritis.
    Type: Application
    Filed: August 4, 2021
    Publication date: October 5, 2023
    Applicant: LG CHEM, LTD.
    Inventors: Jae Uk BAEK, Jung Gyu PARK, Sung Won KIM, Hyun Seo PARK, Sei Hyun CHOI, Myung Won JIN, Min Kyoung LEE
  • Publication number: 20220227743
    Abstract: The present invention relates to: an isooxazoline derivative having an ester moiety, the isoxazoline derivative being a prodrug of a caspase inhibitor, and a pharmaceutical composition containing same.
    Type: Application
    Filed: April 29, 2020
    Publication date: July 21, 2022
    Applicant: LG CHEM, LTD.
    Inventors: Sei Hyun CHOI, Sung Won KIM, Jeong Uk SONG, Jae Uk BAEK, Hyun Seo PARK, Ah Byeol PARK, Jeong Ae KIM, So Yeong KANG, Hee Jeong MOON
  • Publication number: 20220226306
    Abstract: The present invention relates to a pharmaceutical composition for a caspase inhibitor prodrug injection and, more particularly, to a pharmaceutical composition for injection, the composition comprising a caspase inhibitor prodrug or a pharmaceutically acceptable salt or isomer thereof as an active ingredient, and a biocompatible polymer.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Applicant: LG CHEM, LTD.
    Inventors: Sung Won KIM, Bok Tae KIM, Sei Hyun CHOI, Jae Uk BAEK
  • Publication number: 20220226234
    Abstract: The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Applicant: LG CHEM, LTD.
    Inventors: Sung Won KIM, Jae Uk BAEK, Hyun Seo PARK, Myung Won JIN, Jung Gyu PARK, Bok Tae KIM, Sei Hyun CHOI
  • Publication number: 20220213082
    Abstract: The present invention relates to a lactone moiety-bearing isooxazoline derivative, which is a prodrug of a caspase inhibitor, and a pharmaceutical composition comprising same.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 7, 2022
    Applicant: LG CHEM, LTD.
    Inventors: Sei Hyun CHOI, Jeong Uk SONG, Ah Byeol PARK, Jung Joon KIM, Hyun Seo PARK
  • Patent number: 6683095
    Abstract: A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”) is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: January 27, 2004
    Assignee: LG Life Sciences Ltd.
    Inventors: Chang-Yong Hong, Jin-Ho Lee, Tae-Sik Park, Jong-Hyun Kim, Sei-Hyun Choi, Sook-Kyung Yoon, Hyun-Ho Chung, Ho-Sun Son, Eunice Eun-Kyeong Kim, Seong-Gu Ro, Shin-Wu Jeong, Dong-Myung Kim
  • Patent number: 6620831
    Abstract: The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase(CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the compound of formula (1) as an active ingredient together with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: September 16, 2003
    Assignee: LG Life Sciences Ltd.
    Inventors: Jin-Ho Lee, Chang-Yong Hong, Tae-Sik Park, Jong-Hyun Kim, Sei-Hyun Choi, Sook-Kyung Yoon, Hyun-Ho Chung, Shin-Wu Jeong, Kwang-Yeon Hwang, Dong-Kyu Shin
  • Publication number: 20030149034
    Abstract: The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase (CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the compound of formula (1) as an active ingredient together with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 4, 2002
    Publication date: August 7, 2003
    Inventors: Jin-Ho Lee, Chang-Yong Hong, Tae-Sik Park, Jong-Hyun Kim, Sei-Hyun Choi, Sook-Kyung Yoon, Hyun-Ho Chung, Shin-Wu Jeong, Kwang-Yeon Hwang, Dong-Kyu Shin
  • Publication number: 20030125356
    Abstract: The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.
    Type: Application
    Filed: November 1, 2002
    Publication date: July 3, 2003
    Inventors: Chang-Yong Hong, Jin-Ho Lee, Tae-Sik Park, Jong-Hyun Kim, Sei-Hyun Choi, Sook-Kyung Yoon, Hyun-Ho Chung, Ho-Sun Son, Eunie Eun-Kyeong Kim, Seong-Gu Ro, Shin-Wu Jeong, Dong-Myung Kim